DOI: https://doi.org/10.21203/rs.3.rs-2026091/v1
To (1) assess the prevalence of anxiety and depression symptoms in community-dwelling patients with schizophrenia in China during the epidemic; (2) explore possible influencing factors.
Using a cross-sectional survey, we collected 15165 questionnaires. Assessments included demographic information, concern about COVID-19-related information, sleep status, anxiety and depressive symptoms, and accompanying illnesses. The 7-item Generalized Anxiety Disorder (GAD-7) and the 9-item Patient Health Questionnaire (PHQ-9) were used to evaluate depression and anxiety levels. Group comparison was conducted by t-test, ANOVA, or chi-square test wherever suitable with Bonferroni pairwise correction. Multivariate logistic regression were performed to identify predictors for anxiety and depression.
16.9% patients had at least moderate anxiety, and 34.9% had at least moderate depression. T-test showed that females scored higher on GAD-7 and PHQ-9 than males, and patients without accompanying long-standing diseases, who were not concerned about the COVID-19 had lower GAD-7 and PHQ-9 scores. ANOVA showed that participants aged from 30 to 39, with higher education scored higher on GAD-7, and patients with better sleep, having less concern about the COVID-19 had lower GAD-7 and PHQ-9 scores. Regression analysis indicated that participants aged 30–39 and 40–49 positively predicted anxiety, whereas patients aged 30–39 years positively predicted depression. Poor sleep, accompanying diseases, and concerning the COVID-19 pandemic were more likely to experience anxiety and depression.
Chinese community-dwelling schizophrenia patients had high anxiety and depression rates during the pandemic. These patients warrant clinical attention and psychological intervention, especially those with risk factors.
The discovery and rapid progress of the coronavirus disease 2019 (COVID-19) brought huge challenges to the public health and medical communities around the world[1]. The health effects of this virus are worrisome: including death, a strained healthcare system, and economic uncertainty. Similarly, the epidemic may have a devastating effect on psychology and society[2]. Numerous studies assessed the mental health of the general population during the COVID-19 pandemic [3, 4], but there was insufficient research on the emotional impact of schizophrenia patients during the epidemic.
It was reported that patients with schizophrenia had a significantly increased risk of contracting COVID-19 compared to the normal population [5]. High-risk factors included failure to properly recognize self-protection and adherence to preventive behaviors due to impaired cognitive function [6], difficulties in evaluating health information, limitations in access to healthcare[7], and being easily influenced by the ongoing media coverage of the epidemic [8]. Therefore, it is necessary to assess the mental health burden of patients with schizophrenia during the COVID-19 pandemic.
Several studies in China in 2020 showed that hospitalized schizophrenia patients in isolation wards with suspected COVID-19 experienced sleep disturbances had significantly higher scores on depression and anxiety scales and had increased stress compared with general hospitalized schizophrenia patients [9, 10]. In addition, hospitalized patients with schizophrenia suspected of covid-19 were reassessed with significantly more anxiety symptoms than before isolation after 10–14 days of isolation. [10].
Although community-dwelling patients with schizophrenia did not have as narrow and limited social network connections as long-term hospitalized patients [11], they were relatively underreported during the epidemic. A study revealed that many community schizophrenia patients still had some psychiatric symptoms despite their stable condition, and these symptoms affected the life of the patients to a certain extent[12, 11]. Community-dwelling patients with schizophrenia urgently need to be provided with effective intervention methods to help them adapt to life and work during the epidemic. Thus, we intended to explore the psychological burden of community-dwelling patients with schizophrenia during the pandemic. A study indicated that community-dwelling patients with schizophrenia or bipolar disorder experienced more serious anxiety and depressive symptoms compared to community healthy controls during the city lockdown [13]. However, the report did not analyze anxiety and depressive symptoms separately in patients with schizophrenia during the outbreak. A Spanish study showed that compared to the control group, community-dwelling patients with schizophrenia (n = 42) experienced significantly higher scores in Hospital Anxiety and Depression Scale Anxiety (HADS-A) and Hospital Anxiety and Depression Scale Depression (HADS-D) during the COVID-19 pandemic [14]. Moreover, 40.8% of community-dwelling patients with schizophrenia (n = 76) reported depression and 32.9% reported anxiety[15]. In general, studies on depression and anxiety among community-dwelling patients with schizophrenia during the epidemic currently are not enough, and the insufficient sample size is also a deficiency.
Considering the evolving and unpredictable duration of COVID-19, using a web-based cross-sectional and large sample study, the first aim of this study was to examine the mental health burden of community-dwelling patients with schizophrenia during the COVID-19 outbreak, and the second objective was to analyze the potential influence factors. This study assessed the impact of the COVID-19 pandemic crisis on the mental health of community-dwelling patients with schizophrenia. Research on community-dwelling patients with schizophrenia will help provide effective psychological screening and interventions. We hypothesized that community-dwelling patients with schizophrenia had different degrees of anxiety and depression symptoms during the COVID-19 pandemic and that the middle-aged, poor sleep, concerning about epidemic information, and other accompanying long-standing diseases would have an impact on depression and anxiety.
Design, sample and setting
This cross-sectional questionnaire was conducted in a prefecture-level city in China from April 7 to May 10, 2020. According to the local area division, the city has 13 districts, counties (cities) and 2 functional areas. The researchers tried to contact all patients with schizophrenia registered with the local health system, and finally obtained 17,212 questionnaires from patients with schizophrenia. After excluding invalid data, 15,165 questionnaires were available for analysis.
We designed the content of the questionnaire. Community-dwelling patients with schizophrenia under their respective management were contacted by physicians, practicing mental illness prevention in respective districts, counties, and county-level cities, by means of telephone calls, door-to-door visit and outpatient visits, and then physicians filled out online after obtaining the information. Before the start of the study, we trained local physicians, detailing the questionnaire items and quality control of data collection. During the investigation process, the physicians was responsible for explaining the purpose of the study and introducing the content of the questionnaire to ensure that the participants fully understood.
Inclusion criteria were: living in China, being able to communicate normally and meeting the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) diagnosis of schizophrenia. Excluding criteria were: in the acute phase of schizophrenia,accompanying serious medical illness. The 15165 subjects included 7010 male participants (46.2%) and 8155 female participants (53.8%). Age ranged from 10 to 96 years old, and mean age was 55.4 years ± 13.9 S.D.
Ethical approval
The study complied with the ethical standards of the Declaration of Helsinki and was approved by the Ethics Committee of Hangzhou Seventh People’s Hospital. All participants provided written informed consent. Subjects who communicated face-to-face signed a paper informed consent form, and those who communicated by phone signed an electronic informed consent form through an online platform. Because the participants in this study included minors, informed consent was obtained from their parents and/or legal guardians.
Measures
All participants completed a detailed questionnaire, including demographic data, anxiety and depression assessments, and some other information (see supplementary material for details), including sleep status, other accompanying long-standing diseases, concerning about the COVID-19. We defined " long-term diseases “ and explained " sleep status" and “concerning about the COVID-19” in the supplementary material 1.
The Generalized Anxiety Disorder-7 (GAD-7) was adopted to assess the severity of self-reported anxiety[16]. It is composed of 7 items to evaluate how often over the past two weeks the patient has suffered from various issues, such as “difficulty in relaxing” or “excessive worry”. Response categories are “not at all”, “several days”, “more than one week”, and “nearly every day”, scored as 0, 1, 2, and 3, respectively. The total score of the GAD-7 is calculated by summing each item score. The total score ranges from 0 to 21, with a score of 5 indicating that the patient has anxiety. A score of 5, 10, and 15 represent the threshold for “mild”, “moderate”, and “severe” anxiety respectively. Studies showed that the scale has good internal consistency (Cronbach’α=0.92), and the test-retest reliability coefficient was 0.83. When the decomposition value was 10 points, the sensitivity was 89% and the specificity was 82%[17].
PHQ-9, also with good reliability and validity, was employed to screen depressive disorder and measure the severity of symptoms[18]. PHQ-9 is made up of 9 items to evaluate how often over the past two weeks the patient has suffered from nine issues, including depressed mood and anhedonia. Response categories are “not at all”, “several days”, “more than one week”, and “nearly every day”, scored as 0, 1, 2, and 3, respectively. The total score ranges from 0 to 27, with a score of 5 indicating that the patient has depression. A score of 5, 10, 15, and 20 represent the threshold for “mild”, “moderate”, “severe”, and “extremely severe” depression respectively. Nine items of PHQ-9 include anhedonia, depressed mood, sleep disturbance, fatigue, appetite changes, low self-esteem, concentration problems, psychomotor disturbances, and suicidal ideation.
Statistical analysis
Data analyses were conducted using IBM SPSS Statistics software version 19.0 (IBM Corporation, Armonk, NY, USA). Categorical data were described in the case number (percentage) and quantitative data in mean score ± S.D. Group comparison was conducted by t-test, ANOVA, or chi-square test wherever suitable, and pairwise comparison was conducted by Bonferroni test. In order to look for the score differences of PHQ-9 and GAD-7, patients with schizophrenia were sub-grouped into six groups by demographic and clinical status, namely sex, age, marital status, educational level, sleep status, and other accompanying long-standing diseases. Multivariate logistic regression models were performed to identify independent predictors for anxiety and depression respectively. GAD-7 and PHQ-9 scores were first transformed into binary variables with the threshold of mild anxiety or depression and then served as dependent variables in the respective regression models. Sex, age, marital status, educational level, sleep status, other accompanying long-standing diseases, concerning COVID-19, and the degree of concern about the COVID-19. of COVID-19 served as independent variables. Statistical significance was set at a two-sided P-value < 0.05.
General distribution of patient’s anxiety or depression
Among 15165 cases of patients with schizophrenia, the mean score of GAD-7 and PHQ-9 were 8.1±2.1 and 10.4±2.7 respectively, and the prevalence of anxiety and depression was 100%. The proportion of mild anxiety was 83.2%, moderate anxiety accounted for 15.7%, and 1.2% severe. Meanwhile, 65.1% of participants had minimal symptoms of depression, moderate depression rate was 25.7%, the proportion of severe depression was 8.2%, and 1.0% severe. See Table 1 for details.
Table 1 The severity of depression and anxiety in patients during COVID-19
Severity |
GAD-7 |
Severity |
PHQ-9 |
||
n |
(%) |
n |
(%) |
||
Mild |
12612 |
83.2 |
Mild |
9867 |
65.1 |
Moderate |
2377 |
15.7 |
Moderate |
3902 |
25.7 |
Severe |
176 |
1.2 |
Severe |
1249 |
8.2 |
- |
- |
- |
Extremely serious |
147 |
1.0 |
Total |
15165 |
100 |
|
15165 |
100 |
n: number; SD, standard deviation; GAD-7: the 7-item Generalized Anxiety Disorder; PHQ-9: the 9-item Patient Health Questionnaire; COVID-19: 2019 Corona Virus Disease.
Subgroup analyses of questionnaire scores
Regarding the GAD-7 score, group comparison showed that female patients were more anxious than men (t=-2.03, P=0.042). Patients in the 30-39 age group were more anxious than other age groups (F=2.84, P=0.014). Patients receiving university degrees or above had the highest anxiety (F=4.08, P=0.007). Patients with other accompanying long-standing diseases were more anxious than those without other diseases (t=4.18, P<0.001). Patients with poor sleep (F=158.87, P<0.001) had high levels of anxiety. Similarly, PHQ-9 results showed that female patients were more depressed than men (t=-3.27, P=0.001). Patients with poor sleep (F=284.00, P<0.001)had higher levels of depression. Patients with other accompanying long-standing diseases were more depressed than those without other diseases (t=6.86, P<0.001). See Table 2 for details.
Table 2 Comparison of GAD-7 and PHQ-9 scores in patients with different characteristic
Characteristic |
n(%) |
GAD-7 (Mean ±SD) |
F/t/χ2 |
P |
PHQ-9 (Mean ±SD) |
F/t/χ2 |
P |
Sex |
|
|
-2.03 |
0.042 |
|
-3.27 |
0.001 |
Male(%) |
7010(46.2) |
8.1±2.1 |
|
|
10.3±2.5 |
|
|
Female(%) |
8155(53.8) |
8.2±2.2 |
|
|
10.5±2.8 |
|
|
Age(years) |
|
|
2.84 |
0.014 |
|
1.79 |
0.111 |
≤18 |
24(0.2) |
8.1±1.9 |
|
|
10.2±2.3 |
|
|
19~29 |
508(3.3) |
8.0±2.2 |
|
|
10.3±2.9 |
|
|
30~39 |
1647(10.9) |
8.3±2.3 |
|
|
10.6±3.0 |
|
|
40~49 |
2642(17.4) |
8.2±2.1 |
|
|
10.4±2.6 |
|
|
50~59 |
4433(29.2) |
8.1±2.1 |
|
|
10.4±2.6 |
|
|
≥60 |
5911(39.0) |
8.1±2.1 |
|
|
10.4±2.7 |
|
|
Marital status |
|
|
1.69 |
0.092 |
|
0.90 |
0.368 |
With partner |
8607(56.8) |
8.2±2.2 |
|
|
10.4±2.7 |
|
|
Without partner |
6558(43.2) |
8.1±2.1 |
|
|
10.4±2.6 |
|
|
Education(years) |
|
|
4.08 |
0.007 |
|
0.38 |
0.769 |
Illiteracy |
2528(16.7) |
8.1±2.2 |
|
|
10.4±2.8 |
|
|
Primary school |
4786(31.6) |
8.1±2.1 |
|
|
10.4±2.7 |
|
|
Junior high school |
7069(46.6) |
8.2±2.1 |
|
|
10.4±2.6 |
|
|
University and above |
782(5.2) |
8.3±2.2 |
|
|
10.4±2.5 |
|
|
Sleep status |
|
|
158.87 |
<0.001 |
|
284.00 |
<0.001 |
Better |
4256(28.1) |
7.8±1.6 |
|
|
9.8±1.8 |
|
|
Normal |
10243(67.5) |
8.2±2.2 |
|
|
10.6±2.7 |
|
|
Poor |
666(4.4) |
9.1±3.2 |
|
|
12.0±4.4 |
|
|
Accompanying other long-standing disease |
|
|
4.18 |
<0.001 |
|
6.86 |
<0.001 |
Yes |
2648(17.5) |
8.3±2.3 |
|
|
10.7±3.0 |
|
|
No |
12517(82.5) |
8.1±2.1 |
|
|
10.3±2.6 |
|
|
n: number; SD, standard deviation; GAD-7: the 7-item Generalized Anxiety Disorder; PHQ-9: the 9-item Patient Health Questionnaire; COVID-19: 2019 Corona Virus Disease.
Concern about the COVID-19 pandemic
T-test showed that patients who concerned about the COVID-19 scored higher on GAD-7 (t=8.17, P<0.001) and PHQ-9 (t=2.29, P=0.022) respectively, compared to those who do not concerned about the COVID-19. ANOVA showed those with general concern about the COVID-19 scored higher on GAD-7 (F=93.19, P<0.001) and PHQ-9 (F=95.30, P<0.001) respectively than those with less or more concern about the COVID-19. Detailed data was seen in Table 3.
Table 3 Patient’s concern about the COVID-19 pandemic
|
n (%) |
GAD-7 (Mean ±SD) |
F/t |
P |
PHQ-9 (Mean ±SD) |
F/t |
P |
Concerning about the COVID-19 |
|
|
8.17 |
<0.001 |
|
2.29 |
0.022 |
Yes |
12722(83.9) |
8.2±2.1 |
|
|
10.4±2.6 |
|
|
No |
2443(16.1) |
7.8±2.0 |
|
|
10.3±2.9 |
|
|
Total |
15165(100) |
|
|
|
|
|
|
The degree of concern about the COVID-19 |
|
|
93.19 |
<0.001 |
|
95.30 |
<0.001 |
Less |
12055(79.5) |
8.0±2.0 |
|
|
10.2±2.5 |
|
|
General |
2803(18.5) |
8.6±2.5 |
|
|
11.0±3.1 |
|
|
More |
307(2.0) |
8.4±2.8 |
|
|
10.5±3.2 |
|
|
Total |
15615(100) |
|
|
|
|
|
|
n: number; SD, standard deviation; GAD-7: the 7-item Generalized Anxiety Disorder; PHQ-9: the 9-item Patient Health Questionnaire; COVID-19: 2019 Corona Virus Disease.
Multivariate logistic regression models for anxiety and depression among community-dwelling patients with schizophrenia
The details about the multivariate analyses of predictors with logistic regression models for anxiety and depression are shown in Table 4.Our study showed that people in the 30-39 (OR:1.14; 95%CI [0.39,3.4];P=0.811) and 40-49 (OR:1.16 ; 95%CI [1.03,1.32] ; P=0.018)age groups, with other accompanying long-standing diseases (OR:1.15; 95%CI [1.03,1.29];P=0.013) ,who were concerned about the COVID-19 pandemic (OR:1.44 ; 95%CI [1.26,1.65];P<0.001) are more likely to experience anxiety. Good sleep (OR:0.23; 95%CI [0.19,0.28]; P<0.001) can reduce the risk of anxiety. Meanwhile, patients aged 30-39 (OR:1.23 ; 95%CI [1.09,1.38 ] ; P=0.001), with other accompanying long-standing diseases (OR:1.29; 95%CI [1.18,1.42];P<0.001) , concerned about the COVID-19 pandemic (OR:1.49 ; 95%CI [1.34,1.64];P<0.001) are more likely to experience depression. Good sleep (OR:0.26 ; 95%CI [0.22,0.31]; P<0.001) can reduce the risk of depression. Other independent variables are the insignificant predictors in the logistic regression model for anxiety and depression (Table 4). Interestingly, we performed regression analysis separately for males and females and found that male patients with a partner(OR:0.88; 95%CI [0.79,0.97]; P=0.013) had a lower risk of depression (Table 5), and the remaining results did not change much. Detailed data was seen in Table 4-5.
Table 4 Logistic regression analysis of anxiety and depression in patients with schizophrenia in the community
|
|
Anxietya |
Depressionb |
||
|
|
OR(95%CI) |
P |
OR(95%CI) |
P |
Age |
≤18 |
1.14(0.39-3.4) |
0.811 |
0.86(0.35-2.09) |
0.734 |
|
19~29 |
0.94(0.72-1.21) |
0.620 |
0.92(0.75-1.12) |
0.387 |
|
30~39 |
1.26(1.09-1.46) |
0.002 |
1.23(1.09-1.38) |
0.001 |
|
40~49 |
1.16(1.03-1.32) |
0.018 |
1.04(0.94-1.15) |
0.488 |
|
50~59 |
1.03(0.92-1.15) |
0.614 |
1.01(0.93-1.10) |
0.786 |
|
≥60 |
1.00 |
|
1.00 |
|
Sleep status |
Better |
0.23(0.19-0.28) |
<0.001 |
0.26(0.22-0.31) |
<0.001 |
|
Normal |
0.47(0.40-0.56) |
<0.001 |
0.54(0.46-0.63) |
<0.001 |
|
Poor |
1.00 |
|
1.00 |
|
Accompanying other long-standing disease |
Yes |
1.15(1.03-1.29) |
0.013 |
1.29(1.18-1.42) |
<0.001 |
|
No |
1.00 |
|
1.00 |
|
Concerning about the COVID-19 |
Yes |
1.44(1.26-1.65) |
<0.001 |
1.49(1.34-1.64) |
<0.001 |
|
No |
1.00 |
|
1.00 |
|
The degree of concern about the COVID-19 |
Less |
0.78(0.57-1.05) |
0.095 |
0.85(0.67-1.08) |
0.188 |
|
General |
1.38(1.01-1.87) |
0.041 |
1.54(1.20-1.99) |
0.001 |
|
More |
1.00 |
|
1.00 |
|
OR: odds ratio; COVID-19: 2019 Corona Virus Disease.
a Anxiety was defined as a patient with a score of >5
b Depression was defined as a patient with a score of >5
Table 5 Logistic regression analysis of anxiety and depression in male and female patients with schizophrenia in the community
|
|
Anxietya |
Depressionb |
||
|
|
OR(95%CI) |
P |
OR(95%CI) |
P |
Male (N=7010) |
|
|
|
|
|
Marital status |
With partner |
/ |
/ |
0.88( 0.79-0.97) |
0.013 |
|
Without partner |
/ |
/ |
1.00 |
|
Sleep status |
Better |
0.30(0.22-0.41) |
<0.001 |
0.31(0.23-0.40) |
<0.001 |
|
Normal |
0.54(0.41-0.72) |
<0.001 |
0.61(0.47-0.79) |
<0.001 |
|
Poor |
1.00 |
|
1.00 |
|
Accompanying other long-standing disease |
Yes |
/ |
/ |
1.37(1.20-1.57) |
<0.001 |
|
No |
/ |
/ |
1.00 |
|
Concerning about the COVID-19 |
Yes |
1.36(1.12-1.65) |
0.002 |
1.48(1.28-1.72) |
<0.001 |
|
No |
1.00 |
|
1.00 |
|
The degree of concern about the COVID-19 |
Less |
0.66(0.44-1.01) |
0.055 |
0.69(0.49-0.97) |
0.032 |
|
General |
1.18(0.77-1.82) |
0.443 |
1.33(0.94-1.90) |
0.112 |
|
More |
1.00 |
|
1.00 |
|
Female(N=8155) |
|
|
|
|
|
Sleep status |
Better |
0.20(0.16-0.26) |
<0.001 |
0.24(0.19-0.30) |
<0.001 |
|
Normal |
0.44(0.35-0.55) |
<0.001 |
0.50(0.41-0.61) |
<0.001 |
|
Poor |
1.00 |
|
1.00 |
|
Accompanying other long-standing disease |
Yes |
1.16(1.00-1.34) |
0.046 |
1.21(1.07-1.36) |
0.002 |
|
No |
1.00 |
|
1.00 |
|
Concerning about the COVID-19 |
Yes |
1.55(1.29-1.86) |
<0.001 |
1.53(1.33-1.75) |
<0.001 |
|
No |
1.00 |
|
1.00 |
|
The degree of concern about the COVID-19 |
Less |
0.85(0.55-1.30) |
0.454 |
1.00(0.71-1.41) |
0.997 |
|
General |
1.55(1.00-2.40) |
0.050 |
1.75(1.23-2.50) |
0.002 |
|
More |
1.00 |
|
1.00 |
|
OR: odds ratio; COVID-19: 2019 Corona Virus Disease.
a Anxiety was defined as a patient with a score of >5
b Depression was defined as a patient with a score of >5
In the current study, all community-dwelling patients with schizophrenia had different degrees of anxiety and depression during the epidemic period. Moderate to severe anxiety accounted for 16.9%, and the percentage of moderate and above depression is 34.9%, which partly meets our first hypothesis. Regression analysis showed that people aged from 30 to 39, poor sleep, other accompanying long-standing diseases, concerning the COVID-19 pandemic are potential factors of depression and anxiety, which is consistent with our second hypothesis.
15165 cases of community-dwelling patients with schizophrenia in this survey all had mild to severe anxiety and depression, which is supported by previous research. Compared to the control group, community-dwelling patients with schizophrenia experienced significantly higher scores in HADS-A and HADS-D during the covid-19 pandemic [14]. Moreover, 40.8% of community-dwelling patients with schizophrenia (n=76) reported depression and 32.9% reported anxiety[15].
In this study, the GAD-7 and PHQ-9 scores of schizophrenia patients in the 40-49 age group were higher than those of other age groups. Compared with patients with schizophrenia who are older than 60 years, patients aged from 30 to 39 and from 40 to 49 were more likely to experience anxiety and compared with patients older than 60 years old, patients aged 30-39 scored higher in depression. Previous studies showed that during the COVID-19 pandemic, people aged 30-49 had higher scores on epidemic knowledge and will pay more attention to epidemic information, which may increase the risk of depression and anxiety [19]. As we know, the unemployment rate of schizophrenic patients is high, ranging from 80% to 90%, resulting in limited economic income [20]. Middle-aged patients undergo a period of shouldering societal and familial responsibility, although their physiological function is gradually declining. During the epidemic, due to limited social activities [21], the financial resources of patients may be greatly affected, which may lead to greater stress of community schizophrenic patients, resulting in more obvious symptoms of anxiety and depression.
We found that patients with a partner had less serious depression symptoms than those without any partner. Studies have shown that patients with schizophrenia are usually associated with severe damage in many areas of life, including intimacy and social adjustment. Patients with schizophrenia, especially men, are less likely to get married than others[22,23]. Being single may increase the risk of schizophrenia[22,24], and for patients with schizophrenia, being single itself may be a risk of adverse outcomes[25]. Previous studies showed that married patients with schizophrenia or schizoaffective disorder evaluate their quality of life higher than single subjects, and have fewer suicidal ideations than divorced, widowed, or separated subjects[26]. When the COVID-19 pandemic occurred, the situation changed. The epidemic posed a serious threat to patients’ children and families. The consequences of these difficulties may be long-term, partly because environmental risks penetrate the structure and process of the family system[27], while the patient’s partners can take more risks together, so as to reduce the pressure of the patient. Moreover, male schizophrenias who were currently in marital status had the least disease-related symptoms[28].
The results of this study revealed that schizophrenic patients with poor sleep had more severe anxiety and depression symptoms, which was similar to previous studies[29]. Approximately 90% of people diagnosed with depression[30] and approximately 70% of anxiety patients [31] self-reported lack of sleep. Substantial evidence suggested that sleep disturbance was a prodromal symptom of recurrent depressive episodes[32,33]. In addition, depression, anxiety, fear, etc., are more likely to cause sleep problems [34].
We found patients with schizophrenia who accompanied other long-standing diseases were at higher risk of anxiety and depression. A Turkish study showed that the general population with chronic diseases will be more seriously affected by depression and anxiety symptoms, and other accompanying chronic diseases was a risk factor for anxiety. It may be that patients with schizophrenia are more sensitive and aware of how their body feels [35].
The GAD-7 and PHQ-9 scores of community-dwelling patients with schizophrenia who concerned about the COVID-19 were higher than those who did not concerned. Besides, the group comparison above showed that the anxiety and depression symptoms of patients with general concern about the epidemic were more serious than those with less or more concern. For the first result, this may be because patients who didn’t concern about the COVID-19 at all couldn’t understand the severity of the epidemic, and were less worried about the health problems of the epidemic, which led to insignificant anxiety and depression symptoms. For those who are occasionally concerned about the epidemic, concerning that the methods of controlling infectious diseases including risk communication, hygiene habits, social distancing, and vaccines were safe and effective [36] their anxiety and depression were naturally reduced. Patients who were moderately concerned but not thoroughly concerned about the outbreak experienced the most severe symptoms of depression and anxiety, probably because they were not ignorant, but overwhelmed by seeing more information on COVID-19 [21]. Some of the information or relevant knowledge they obtained may be superficial, especially in uncertain periods. Conspiracy theories and rumors are particularly popular during the pandemic. For example, they saw a lot of rumors but did not further obtain rumor refutation information. Social media may be double-sided under the promotion of some people [36]. Since the information obtained by patients was too much but not in-depth enough and the information cannot be distinguished from true and false, it was more likely to have a sense of uncontrollability and produce more serious anxiety and depression.
As our findings showed, patients with schizophrenia had obvious psychological stress responses such as anxiety and depression during the epidemic. Previous research has shown that pandemics can lead to unemployment and family poverty, separation of family members, and social isolation [36]. At the same time, the number of patients being screened for safety reasons decreases, and individuals with psychiatric symptoms may have difficulty accessing medical assistance[35]. Therefore, we need to focus on the mental health of patients in a timely and adequate manner. These patients are prevented from experiencing more severe consequences after stimulation, such as worsening of psychiatric symptoms and disease relapse [37]. Community grassroots medical staff and members of care and rescue groups need to focus on follow-up and emotional counseling for patients with the above characteristics. Of course, this mental health program should not increase the burden on healthcare providers and the risk of spreading the infection to other[36].
This survey also has certain limitations. First, due to the special period of epidemic prevention and control, the patient’s mental health questionnaire survey was delivered by home visits, telephone calls, outpatient clinics, etc. Different delivering forms may cause misunderstandings and inaccuracy of the results. Although physicians had unified the standards for questionnaire interviews, different transmission forms may still cause misunderstandings and inaccurate results. In this study, the means of telephone or face-to-face interviews were used. Face-to-face communication may help patients understand better than phone conversations, and the results obtained were relatively more accurate. Second, in order to obtain patient information conveniently, all results were derived from self-report scales, although physicians tried their best to explain and explain the items, but this could still lead to biases of patients’ recall. Third, this study was mainly based on the evaluation of patients by local physicians practicing mental illness prevention and the results may be affected by their subjective evaluation. Finally, we did not evaluate the depression or anxiety symptoms of these patients before the outbreak, which leads to a lack of longitudinal comparison.
This was the first study to investigate the psychological burden of community-dwelling patients with schizophrenia with a large sample during the COVID-19 epidemic. This study demonstrated that during the epidemic period, moderate and severe anxiety and depression symptoms were common in patients with schizophrenia. In addition, we found that in the current study, the 30-39 age group, sleeping poorly, with other accompanying long-standing diseases, concerning about the COVID-19 were risk factors of anxiety or depression. Besides, patients with general concern of COVID-19 had more severe symptoms of depression and anxiety. Living with a partner was a protective factor for depression in male patients. Our results indicated that community-dwelling patients with schizophrenia are prone to anxiety and depression, and we need to strengthen targeted psychological interventions for community-dwelling patients with schizophrenia during the COVID-19 pandemic based on the above influencing factors.
Acknowledgments
The authors wish to thank all the patients who participated in this study and thank the support of the Science and Technology Department of Zhejiang Province (LGF21H090006).
Contributions
H.D Song and J.S Tang designed the study. X.H Sun, Q.S Zhu and Y. Zhao collected the clinical study. S.S Chen conducted the methodology and statistical analysis. S.S Chen, J.S Tang and H.D Song contributed to the writing and editing of the article. All authors have read and approved the published version of the manuscript.
Funding
This work was supported by the Public Projects of Science and Technology Department of Zhejiang Province (LGF21H090006).
Conflict of interest
The authors declare no conflict of interests.
Ethics approval
All participants provided written informed consent. The study complied with the ethical standards of the Declaration of Helsinki and was approved by the Ethics Committee of Hangzhou Seventh People’s Hospital and therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.